Frazer Giles MORGAN,Mark Jonathan MAIN,Roger PALFRAMAN,David KIRKE
申请号：
US16346051
公开号：
US20190247303A1
申请日:
2017.10.31
申请国别(地区):
US
年份:
2019
代理人:
摘要：
An inhalable powder composition comprises a) an antagonistic antibody which binds human IL-13, b) leucine and c) trehalose. The antibody may comprise a heavy chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:3 and a light chain, wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:1. Also described is the use of such compositions in the treatment of asthma, as well as inhalers containing such compositions.
